RESUMEN
The results of studies on the influence of zinc oxide nanoparticles (ZnO-NPs) on the structural, thermal and optical properties of thin films of mixtures of phenyl-C71-butyric acid methyl ester (PCBM) with poly[3-hexylthiophene] (P3HT) of various molecular weights are described in this article. The structural properties of the layers of: polymers, mixtures of polymers with fullerenes and their composites with ZnO-NPs were investigated using X-ray diffraction. Whereas their glass transition temperature and optical parameters have been determined by temperature-dependent spectroscopic ellipsometry. The presence of ZnO-NPs was also visible in the images of the surface of the composite layers obtained using scanning electron microscopy. These blends and composite films have also been used as the active layer in bulk heterojunction photovoltaic structures. The molecular weight of P3HT (Mw = 65.2; 54.2 and 34.1 kDa) and the addition of nanoparticles affected the power conversion efficiency (PCE) of the obtained solar cells. The determined PCE was the highest for the device prepared from the blend of P3HT:PCBM with the polymer of the lowest molecular weight. However, solar cells with ZnO-NPs present in their active layer had lower efficiency, although the open-circuit voltage and fill factor of almost all devices had the same values whether they contained ZnO-NPs or not. It is worth noting that thermal studies carried out using temperature-dependent ellipsometry showed a significant effect of the presence of ZnO-NPs on the value of the glass transition temperature, which was higher for composite films than for films made of a polymer-fullerene blend alone.
RESUMEN
The article presents the thermal and physical properties of PMMA composite films with the addition of Nb2O5 nanoparticles. The addition of nanoparticles to PMMA mainly influenced the optical transmission and glass transition temperature of composite films compared to pure PMMA. It is clearly visible in the results of the conducted ellipsometric and differential scanning calorimetry tests. X-ray studies showed that the heat treatment of the samples resulted in the ordering of the polymer structure (flattening of the polymer chains). Examining the surface of the samples with scanning electron microscopy, it can be seen that Nb2O5 nanoparticles formed unusual, branched formations resembling "snowflakes".
RESUMEN
PURPOSE: Gestational diabetes (GDM) is related to increased maternal and neonatal morbidity. Maternal hyperglycemia causes fetal hyperglycemia and consequently fetal hyperinsulinism. The impaired glucose metabolism will lead to prenatal and postnatal complications. The main issue of this study is the influence of GDM in evaluating Doppler flow measurements in the umbilical artery (UA). MATERIALS AND METHODS: Pregnancies from gestational age > 34 + 0 were included in this case control study. The study period was 18 months. The last Doppler measurement in pregnancies with GDM (diet-controlled and insulin-dependent) was compared to the healthy control group. Our collected data included the last prenatal Doppler flow recordings (resistance index (RI) in the umbilical artery (UA)). RESULTS: In women with diet-controlled GDM, a significant decrease in the RI (p = 0.002) in the UA has been observed. Insulin-treated diabetic and healthy control pregnancies showed no difference in the RI. CONCLUSION: Doppler flow examinations with RI measurements in patients with GDM differ significantly with respect to healthy controls. In insulin-treated women the RI indices are not different from the control group, while in the diet-controlled group a significant decrease was noted and additionally might show a possible maternal metabolic dysfunction.
Asunto(s)
Diabetes Gestacional/diagnóstico por imagen , Placenta/irrigación sanguínea , Tercer Trimestre del Embarazo , Ultrasonografía Doppler , Ultrasonografía Prenatal , Arterias Umbilicales/diagnóstico por imagen , Resistencia Vascular/fisiología , Adolescente , Adulto , Diabetes Mellitus Tipo 1/diagnóstico por imagen , Diabetes Mellitus Tipo 1/terapia , Diabetes Gestacional/terapia , Dieta para Diabéticos , Femenino , Enfermedades Fetales/diagnóstico por imagen , Humanos , Hiperglucemia/diagnóstico por imagen , Hiperinsulinismo/diagnóstico por imagen , Recién Nacido , Insulina/administración & dosificación , Persona de Mediana Edad , Embarazo , Valores de Referencia , Adulto JovenRESUMEN
BACKGROUND: Indications for long-term anticoagulation are expanding. Osteoporosis is a complication which can develop after prolonged treatment with unfractionated heparin and is probably multifactorial. Data on osteoporosis associated with low-molecular-weight heparins (LMWH) are contradictory. Vitamin K participates in bone metabolism and since oral anticoagulants antagonize vitamin K, their use may also increase the risk of osteoporosis. AIM: To assess and compare the effects of long-term secondary venous thromboembolic prophylaxis with LMWH or acenocoumarol on bone structure. METHODS: We assessed bone mineral density (BMD) by densitometry in 86 patients receiving LMWH or acenocoumarol for 3-24 months. The initial BMD was compared to the final result expressed as the percentage difference. The Z-score was also assessed and defined for individual patients as the number of standard deviations of BMD from its ideal value calculated for age and sex groups. RESULTS: Excessive decrease in BMD was evidenced, which seemed to relate to the duration as well as type of treatment. At 1 and 2 years of follow-up, the mean decrease in BMD of the femur was 1.8% and 2.6% in patients on acenocoumarol and 3.1 and 4.8% in patients on enoxaparin, respectively. CONCLUSIONS: Long-term exposure to treatment and prophylaxis of venous thromboembolism cause a modest but progressive decrease in BMD, more evident in patients on LMWH than on acenocoumarol. It might be advisable to perform densitometry before starting long-term anticoagulation and to repeat it every 12 months, especially in patients with concomitant risk factors for osteoporosis in order to identify patients in need of its prophylaxis.
Asunto(s)
Acenocumarol/efectos adversos , Anticoagulantes/efectos adversos , Densidad Ósea/efectos de los fármacos , Heparina de Bajo-Peso-Molecular/efectos adversos , Tromboembolia/tratamiento farmacológico , Trombosis de la Vena/tratamiento farmacológico , Acenocumarol/administración & dosificación , Adulto , Anciano , Anticoagulantes/administración & dosificación , Enfermedades Óseas Metabólicas/inducido químicamente , Enoxaparina/administración & dosificación , Enoxaparina/efectos adversos , Femenino , Fémur , Heparina de Bajo-Peso-Molecular/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Nadroparina/administración & dosificación , Nadroparina/efectos adversos , Osteoporosis/inducido químicamente , Prevención Secundaria , Tromboembolia/complicaciones , Tromboembolia/prevención & control , Factores de Tiempo , Trombosis de la Vena/complicaciones , Trombosis de la Vena/prevención & controlAsunto(s)
Acenocumarol/efectos adversos , Densidad Ósea/efectos de los fármacos , Heparina de Bajo-Peso-Molecular/efectos adversos , Acenocumarol/administración & dosificación , Adulto , Anciano , Anticoagulantes/administración & dosificación , Anticoagulantes/efectos adversos , Femenino , Heparina de Bajo-Peso-Molecular/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Osteoporosis/inducido químicamente , Estudios RetrospectivosRESUMEN
20 consecutive patients with thromboembolic pulmonary hypertension underwent pulmonary thromboendarterectomy. Mean pulmonary artery pressure decreased from mean 49.9 +/- 9.8 to 25.1 +/- 8.8 mm Hg (p < 0.0001), pulmonary vascular resistance decreased from mean 5.58 +/- 2.58 to 1.62 +/- 0.79 mm Hg/l*min-1 (p < 0.0001) and cardiac output increased from 3.71 +/- 1.18 to 6.92 +/- 1.64 l/min. Sixteen patients had marked clinical improvement. Two patients died in early and 2 patients in late postoperative period due to unrelieved pulmonary hypertension and postoperative complications.
Asunto(s)
Endarterectomía , Hipertensión Pulmonar/complicaciones , Tromboembolia/complicaciones , Tromboembolia/cirugía , Adulto , Anciano , Gasto Cardíaco , Endarterectomía/efectos adversos , Femenino , Humanos , Hipertensión Pulmonar/fisiopatología , Masculino , Persona de Mediana Edad , Arteria Pulmonar/fisiopatología , Resistencia VascularRESUMEN
The aim of the study was to assess effectiveness and safety of the LGM inferior vena cava (IVC) filters in patients with venous thromboembolic disease. In the Department of Internal Medicine of Institute of Tuberculosis and Lung Diseases in Warsaw 79 LGM IVC filters have been inserted since 1993. Indications for filters placement were as follows: recurrent pulmonary embolism (pe) despite anticoagulation--17 patients (pts), severe bleeding complications of thrombolytic or anticoagulant therapy--11 pts, contraindications for thrombolytic and/or anticoagulant treatment--5 pts, massive pe--14 pts, chronic thromboembolic-major vessel pulmonary hypertension (CTEPH)--30 pts, extensive deep vein thrombosis of lower limbs or vena cava inferior in patients with urgent indications for surgery--24 pts. Each filter placement was preceded by cavography. The diagnostic procedures (mainly ultrasonography) were performed after 3-6 and 12 months in the first year then once yearly during follow-up period. Oral anticoagulants (OA) or low-molecular-weight heparins (LMWH) were instituted in the majority of patients. 58 patients are still alive, 21 patients died. Only two non-fatal episodes of recurrent pe were documented. Other complications were rare and insignificant. We have not observed excess rate of recurrent deep venous thrombosis nor thrombosis at the filter site. The LGM IVC filters are effective and safe in such selectively chosen group of patients.
Asunto(s)
Embolia Pulmonar/prevención & control , Tromboflebitis/terapia , Filtros de Vena Cava , Administración Oral , Anticoagulantes/administración & dosificación , Contraindicaciones , Femenino , Estudios de Seguimiento , Heparina de Bajo-Peso-Molecular/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Embolia Pulmonar/etiología , Recurrencia , Tromboflebitis/complicacionesRESUMEN
A broad spectrum of indications for low molecular weight heparin (LMWH) requires an assessment of side effects especially during prolonged administration. There are common risk factors for venous thromboembolism (VTE) and osteoporosis; heparin is "the drug of choice" for VTE treatment. The aim of our study was to assess the effect of treatment and prophylaxis with LMWH (enoxaparine sodium) and oral anticoagulant (acenocoumarol) for bone structure. Material consists of in- and outpatients. 49 densitometries were performed in 31 patients (in 15 cases double examination). We observed a decrease of bone mineral density in comparison to the initial examination in most cases: mean change of bone mass for examined areas was 3.05%.
Asunto(s)
Acenocumarol/efectos adversos , Anticoagulantes/efectos adversos , Densidad Ósea/efectos de los fármacos , Heparina de Bajo-Peso-Molecular/efectos adversos , Acenocumarol/administración & dosificación , Adulto , Anciano , Anticoagulantes/administración & dosificación , Femenino , Heparina de Bajo-Peso-Molecular/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Osteoporosis/inducido químicamente , Osteoporosis/prevención & control , Factores de Riesgo , Tromboflebitis/prevención & controlRESUMEN
The aim of the study was to assess effectiveness and safety of inferior vena cava filters in patients with cancer and concurrent thromboembolic disease. The LGM filters were inserted in 10 cancer patients. Diagnosis of malignancy was established prior filter placement in 8 patients and after the procedure in 2 patients. Follow-up physical examination and ultrasound procedures (Echo, Duplex-Doppler) were performed after 1, 3, 6, 12, 24 months. Mean period of observation lasted 12 month. All patients received prolonged anticoagulation either oral anticoagulants or low molecular weight heparins after filter placement. Our results confirm that the LGM filters are effective and well tolerated in patients with malignancies. There were no important complications both early and late related to filter placement and no evidence of recurrent pulmonary emboli.
Asunto(s)
Neoplasias/complicaciones , Tromboembolia/complicaciones , Filtros de Vena Cava , Adulto , Anciano , Seguridad de Equipos , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Estudios RetrospectivosRESUMEN
The analysis of 49 fatal cases of venous thromboembolism--VTE (15% of total ambulatory patients number during long observation was performed. The advanced age of patients, multiple risk factors, underlying circulatory and respiratory tract diseases, malignancies, previous episodes of VTE especially with secondary pulmonary hypertension were the most important factors determining fatal prognoses in those patients.
Asunto(s)
Tromboembolia/mortalidad , Tromboembolia/prevención & control , Adulto , Anciano , Anciano de 80 o más Años , Comorbilidad , Femenino , Humanos , Hipertensión Pulmonar/epidemiología , Masculino , Persona de Mediana Edad , Neoplasias/epidemiología , Recurrencia , Enfermedades Respiratorias/epidemiología , Factores de Riesgo , Análisis de Supervivencia , Tromboembolia/complicaciones , Enfermedades Vasculares/epidemiologíaRESUMEN
We have attempted to determine the outcome of 87 out-patients who were lost from follow-up. Several factors have been assessed: causes of lost from follow-up duration of oral anticoagulation, recurrent venous thromboembolic events, cause of death (if applicable).
Asunto(s)
Anticoagulantes/uso terapéutico , Cooperación del Paciente/estadística & datos numéricos , Tromboembolia/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Atención Ambulatoria , Causas de Muerte , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Polonia , Recurrencia , Estudios Retrospectivos , Tromboembolia/mortalidad , Resultado del TratamientoRESUMEN
In the Department of Medicine at the Institute of Tuberculosis and Lung Diseases 50 LGM inferior vena cava filters have been inserted since 1993. Indications for filters placement were as follows: recurrent pulmonary embolism (PE) despite anticoagulation-16 patients (pts), severe bleeding complications of thrombolytic or anticoagulant therapy-9 pts, contraindications for thrombolytic and/or anticoagulant treatment-3 pts, massive PE-6 pts, chronic thromboembolic-major vessel pulmonary hypertension (CTEPH)-18 pts, extensive deep vein thrombosis of lower limbs or vena cava inferior in patients with urgent indications for surgery-10 pts. In every patient diagnostic procedures were performed after 1, 3, 6, 12, 24 and 36 months of follow-up period. Only one non-fatal episode of recurrent PE was documented. Other complications were rare and insignificant. The LGM inferior vena cava filters are effective and safe in such selectively chosen group of patients.
Asunto(s)
Embolia Pulmonar/terapia , Filtros de Vena Cava , Femenino , Estudios de Seguimiento , Humanos , Hipertensión Pulmonar/mortalidad , Hipertensión Pulmonar/terapia , Masculino , Persona de Mediana Edad , Embolia Pulmonar/mortalidad , Recurrencia , Tasa de Supervivencia , Tromboflebitis/mortalidad , Tromboflebitis/terapia , Resultado del Tratamiento , Vena Cava Inferior/cirugíaRESUMEN
CTEPH have not been widely recognised until recently. Introduction of the new, sophisticated, non-invasive diagnostic tools accounts for rapid progress in that field. Patients with high pulmonary hypertension have a very poor prognosis. Medical treatment (vasodilators, anticoagulants) does not change outcome. Pulmonary thromboendarterectomy is the only therapeutic option for the patients. It is essential to prevent further episodes of pulmonary embolism both over the long term and during the high risk perioperative period by means of inferior vena cava filters. In the Department of Medicine, Institute of Tuberculosis and Lung Diseases 18 LGM ivc filters have been inserted in patients with CTEPH since 1994. In 7 patients PTE was performed-in 5 cases good result was achieved, 2 patients died after surgery. In the latter group 5 patients died mainly because of severe heart failure. Only one non-fatal episode of pulmonary embolism was observed. It should be concluded that the LGM ivc filters are safe and effective in preventing episodes of pulmonary embolism in patients with CTEPH.
Asunto(s)
Hipertensión Pulmonar/complicaciones , Embolia Pulmonar/prevención & control , Tromboembolia/terapia , Filtros de Vena Cava , Enfermedad Crónica , Femenino , Humanos , Masculino , Persona de Mediana Edad , Tromboembolia/complicaciones , Resultado del Tratamiento , Vena Cava InferiorRESUMEN
In 18 patients with proximal deep venous thrombosis (PDVT) confirmed by phlebography, no symptoms and signs of pulmonary embolism (PE) were observed. All patients were treated with nadroparin. During first 6 days of treatment in all patients perfusion lung scans were performed. 8 patients (44.4%) of all group developed lung scans positive for PE (silent PE). Period of successful treatment of PDVT was 10 days. No evidence of recurrent PE were observed during the period of treatment. We conclude that: 1. Frequency of silent PE in patients with PDVT is very high-lack of symptoms and signs of PE does not exclude the presence of PE in this group of patients. 2. In all patients with PDVT perfusion lung scan should be performed even in cases with no symptoms and signs of PE. 3. Low molecular weight heparins administered subcutaneously are effective in treatment either silent PE or PDVT.
Asunto(s)
Embolia Pulmonar/diagnóstico por imagen , Tromboflebitis/complicaciones , Adulto , Anciano , Anciano de 80 o más Años , Anticoagulantes/uso terapéutico , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Nadroparina/uso terapéutico , Flebografía , Embolia Pulmonar/epidemiología , Embolia Pulmonar/etiología , Cintigrafía , Tromboflebitis/diagnóstico por imagen , Tromboflebitis/tratamiento farmacológicoRESUMEN
12 patients (7 male and 5 female) with confirmed pulmonary embolism (PE) with: angiography-5 cases, conventional contrast-enhanced CT-2 cases, echocardiography-2 cases, autopsy-3 cases were diagnosed as clinically acute PE. Criteria of clinically acute PE were: cardiac arrest-1 case-2 cases, shock-1 case, acute cor pulmonale-9 cases and acute cor pulmonale with shock. All patients were treated with heparin, administered with therapeutic prolongation of aPTT. Clinically acute PE (if possible confirmed with angiography, TC and/or echocardiography) was treated with rtPA administered in 10 minutes lasting bolus in doses 0.6-0.8 mg per kg of body weight (50 mg of rtPA during 10 minutes administered into peripheral veins). In 9 patients with pulmonary hypertension, significant decrease of tricuspidal gradient (measured echocardiographically during several hours after administration of rtPA) was documented. Improvement in PaO2, SaO2 and decrease of heart rate and respiratory rate were also achieved. No serious bleeding complications were observed after mentioned treatment. Control investigations (conventional contrast-enhanced CT and spiral CT) performed several days after rtPA administration revealed thrombus in pulmonary artery. We conclude: I rtPA administered in bolus simultaneously with heparin significantly decreased pulmonaryhypertension; rtPA administered simultaneously with heparin is safe method of treatment of PE; hemodynamic improvement after administration of rtPA is not univocal with full fibrynolitic effect.
Asunto(s)
Heparina/administración & dosificación , Embolia Pulmonar/tratamiento farmacológico , Terapia Trombolítica , Activador de Tejido Plasminógeno/administración & dosificación , Adulto , Anciano , Ecocardiografía , Femenino , Humanos , Hipertensión Pulmonar/prevención & control , Masculino , Persona de Mediana Edad , Embolia Pulmonar/diagnóstico , Proteínas Recombinantes , Tomografía Computarizada por Rayos XRESUMEN
43-year old woman, with considerable overweight had been admitted to Intensive Medical Care Unit with suspicion of pulmonary embolism (PE). The patient had the limb immobilized in gypsum for last several weeks. This episode was tangled with recurrent thrombosis of deep veins in the left limb, treated with heparin and oral anticoagulants irregularly without sufficient control. Taking into consideration the data of anamnesis, clinical picture and the results of ECG, chest X-ray, gasometric and echocardiographic examination we got much closer to the recognition of PE. Our suspicion of PE was confirmed by the result of pulmonary angiography. Indications for thrombolytic treatment (r-tPA) had been established. During the following hours considerable improvement of general state was observed. The therapy was continued with constant drip infusion of heparin. No prolongation of therapeutic PTT was observed. The deficit of AT III was diagnosed. In this situation the patient was given AT III to obtain normalization of its level and therapeutic extension of PTT. Therefore there were settled indications for the operation of uterus with myoma changes. As the rich thrombolytic material in the leg's vein was found the patient was implanted LGM Filter, with excellent prophylactic effect (no PE in perioperative period). The clinical course of our case enabled to present most of diagnostic, therapeutic and preventive methods applied in venous thromboembolism.
Asunto(s)
Embolia Pulmonar/diagnóstico , Embolia Pulmonar/terapia , Enfermedad Cardiopulmonar/complicaciones , Tromboflebitis/complicaciones , Administración Oral , Adulto , Anticoagulantes/administración & dosificación , Femenino , Heparina/administración & dosificación , Humanos , Tiempo de Tromboplastina Parcial , Embolia Pulmonar/etiología , Proteínas Recombinantes , Tromboflebitis/diagnóstico , Tromboflebitis/tratamiento farmacológico , Activador de Tejido Plasminógeno/administración & dosificación , Filtros de Vena CavaRESUMEN
In 10 patients with thromboembolic disease 1 Gunther filter and 9 LGM filters were inserted. Indications for filter placement were: pulmonary hypertension caused by recurrent pulmonary embolism in 3 cases; planned surgery in 2 patients with pulmonary embolism and deep venous thrombosis; recurrent pulmonary embolism despite of anticoagulant treatment in 2 cases, previously performed thrombo-endarterectomy in 1 case; contraindications for anticoagulant treatment in 1 case and complications of anticoagulant therapy also in 1 case. No serious complications after filter placement were observed.
Asunto(s)
Embolia Pulmonar/prevención & control , Tromboembolia/terapia , Filtros de Vena Cava , Adulto , Anciano , Femenino , Humanos , Hipertensión Pulmonar/terapia , Masculino , Persona de Mediana Edad , Tromboflebitis/terapia , Resultado del TratamientoRESUMEN
Case of recurrent, clinically acute massive pulmonary embolism treated with rtPA (administered 0.6 mg/kg, during 10 minutes simultaneously with heparin) is presented. Minimal clinical improvement was observed after mentioned procedure. Good clinical response was achieved after LGM filter insertion into vena cava inferior. Clinical course was complicated by Dressler-like syndrome successfully treated with steroids. Problems of massive pulmonary embolism, vena cava filter prophylaxis and pericardial complication of pulmonary embolism are discussed.